Get started
Author

Anne Sophie Platzbecker

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
2025 · Anne Sophie Platzbecker, Julia-Annabell Georgi, et al. · Blood · 8
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 · Luca Lanino, Anthony M. Hunter, et al. · Journal of Clinical Oncology · 4
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
2026 · Maria Julia Montoro, Pamela Acha, et al. · Leukemia · 2
POSTER: MPN-756: CPX-351 vs Standard of Care as Bridging to AlloHCT in Patients With Higher-Risk Myelodysplastic Neoplasms or Oligoblastic Acute Myeloid Leukemia: Results of the Randomized Phase 2 PALOMA Study
2026 · Uwe Platzbecker, Martina Crysandt, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
2026 · Heike Weidner, Elena Tsourdi, et al. · Leukemia
PDF
MPN-756: CPX-351 vs Standard of Care as Bridging to AlloHCT in Patients With Higher-Risk Myelodysplastic Neoplasms or Oligoblastic Acute Myeloid Leukemia: Results of the Randomized Phase 2 PALOMA Study
2026 · Uwe Platzbecker, Martina Crysandt, et al. · Clinical Lymphoma Myeloma & Leukemia
Enhancing the resilience of remote patient monitoring and hospital-at-home systems: a digital-twin-based framework
2026 · Max Ostermann, Anne Sophie Platzbecker, et al. · npj Health Systems
PDF
Development and early feasibility testing of machine-learning algorithms to non-invasively assess hemoglobin levels
2026 · Simon Hefner, Philipp Stoffers, et al. · npj Biomedical Innovations.
PDF
Works count: 8
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type